What Clinical Contraindications Must Be Screened Prior To Performing Deep Skin Resurfacing Procedures? Essential Safety Checks

Before deep skin resurfacing, clinicians must screen for conditions that impair healing, increase infection risk, or make pigment and scarring complications more likely. Essential screening includes recent oral isotretinoin use, active infection, HSV history, keloid or hypertrophic scarring, connective-tissue disease, prior radiation or burns, immune impairment, smoking, recent UV exposure, skin phototype, relevant eyelid surgery, and the patient’s ability to follow postoperative care. Some findings are absolute reasons to defer treatment, while others require modified settings, prophylaxis, or specialist consultation.

Deep resurfacing is controlled wounding. The procedure is safest when the patient has adequate dermal appendages for re-epithelialization, reliable tissue vascularity, no active infection, and a low risk of abnormal scarring or pigmentary injury.

Screen for Factors That Impair Healing

Recent oral isotretinoin use

Recent or current oral isotretinoin use is a major contraindication to aggressive resurfacing because sebaceous glands and other adnexal structures contribute to re-epithelialization and repair.

The references identify a deferral period ranging from 6 to 12 months, depending on the procedure, device, and clinical protocol. Because recommendations vary, clinicians should follow current product labeling, specialty guidance, and institutional policy rather than applying one interval to every resurfacing procedure.

Compromised adnexal structures

Prior head and neck radiation, deep burns, scleroderma, significant dermal fibrosis, or severe scarring can damage the adnexal structures needed for healing.

These conditions may make resurfacing unpredictable, particularly when treatment is deep or performed over previously injured skin. They should prompt careful risk assessment and may contraindicate treatment in the affected area.

Active connective-tissue disease

Active disorders such as scleroderma, lupus, or Sjögren syndrome may impair collagen remodeling, vascular function, or immune response.

Active disease is a strong reason to defer aggressive resurfacing. Even when disease is controlled, treatment should be considered only after assessing disease activity, medications, photosensitivity, and wound-healing risk.

Smoking and vascular compromise

Active smoking reduces tissue oxygenation and microvascular perfusion. This can delay healing and increase the risk of necrosis, infection, and poor scarring.

Smoking status should be documented during consultation. Deep resurfacing should generally be deferred until vascular and wound-healing risks are acceptably controlled under the clinician’s protocol.

Exclude Infection and Reactivation Risks

Active bacterial, viral, or fungal infection

An active infection in or near the treatment field is a contraindication to resurfacing. This includes bacterial, viral, and fungal infections, as well as active inflammatory skin conditions that could worsen after barrier disruption.

Treatment should be postponed until the condition has resolved and the skin barrier is intact.

Herpes simplex virus

A history of herpes labialis or recurrent HSV is particularly important for full-face and perioral ablative procedures because epidermal removal can trigger viral reactivation.

Active HSV is a reason to defer treatment. A remote history of HSV is not necessarily a permanent contraindication, but it generally requires an antiviral prophylaxis plan, such as clinician-prescribed acyclovir or valacyclovir beginning on or before treatment and continuing through the vulnerable postoperative period.

Impaired immune function

Patients with significant immunosuppression may have higher risks of infection, delayed healing, and poor wound control.

The clinician should review systemic disease and immunosuppressive medications before proceeding. The depth and extent of resurfacing may need to be reduced, or treatment deferred altogether.

Assess Abnormal Scarring Risk

Keloids and hypertrophic scars

A personal tendency toward keloid or hypertrophic scar formation is a major contraindication to deep resurfacing because controlled thermal or chemical injury may produce excessive scar tissue.

This risk remains clinically significant even when treatment is technically precise. A detailed history should include previous surgical, traumatic, acne-related, and cosmetic scars.

Prior procedures that alter dermal architecture

Previous deep chemical peels, dermabrasion, burns, radiation, or other procedures may leave dermal fibrosis or reduced tissue elasticity.

The treatment area should be examined for altered texture, tethering, thin skin, or existing fibrosis. These findings may require conservative treatment or make deep resurfacing inappropriate.

Evaluate Pigmentary and Light-Related Risks

Fitzpatrick skin phototype

Patients with Fitzpatrick skin types IV to VI have a higher risk of post-inflammatory hyperpigmentation after ablative resurfacing.

Darker phototypes are not automatically excluded from every resurfacing procedure, but aggressive treatment requires careful risk-benefit assessment. Conservative fluence, fewer passes, staged treatment, or an Er:YAG approach may be considered according to the device and clinical protocol.

Existing pigmentary disease

Active melasma, severe pre-existing hyperpigmentation, or a strong history of post-inflammatory hyperpigmentation can worsen after resurfacing.

These conditions should be treated or stabilized before proceeding. The clinician should explain that resurfacing may improve texture while aggravating dyschromia.

Recent UV exposure

Recent tanning, sunburn, or substantial ultraviolet exposure increases the risk of pigmentary complications and abnormal recovery.

Treatment should be deferred until the skin has returned to its baseline condition, with strict photoprotection before and after the procedure.

Photosensitivity

Photosensitivity from collagen vascular disease or light-sensitizing medications requires specific review before laser treatment.

The medication list should include prescription drugs, over-the-counter products, and topical agents that may alter photosensitivity or skin integrity.

Estrogen-related pigment risk

Elevated estrogen exposure, including oral contraceptives or hormone therapy, may increase the likelihood of hyperpigmentation, particularly in patients predisposed to melasma.

This is generally a risk modifier rather than an automatic contraindication. The decision should account for the patient’s pigment history, current melasma activity, treatment depth, and ability to maintain photoprotection.

Review Procedure-Specific Anatomical Risks

Prior external lower blepharoplasty

A history of external lower blepharoplasty can increase the risk of postoperative ectropion when ablative resurfacing is performed around the lower eyelids.

The clinician should assess lower-eyelid position, elasticity, laxity, and the extent of planned treatment. Infraorbital treatment may be inappropriate or may require substantially more conservative settings.

Reduced eyelid elasticity

Pronounced lower-eyelid laxity or poor lid support increases the risk of ectropion after periorbital resurfacing.

This risk is anatomical and cannot be eliminated by laser precision alone. Patients with significant laxity may require specialist evaluation or exclusion from deep periorbital treatment.

Suspicious lesions and skin cancer

Active skin cancer or a suspicious lesion in the treatment field should be evaluated before resurfacing.

Resurfacing should not proceed over an undiagnosed lesion because treatment can obscure clinical findings and complicate subsequent assessment.

Confirm the Patient Can Safely Complete Recovery

Ability to follow wound-care instructions

Deep resurfacing requires strict postoperative wound care, infection surveillance, sun avoidance, and follow-up.

An inability or unwillingness to follow these requirements is a contraindication because poor aftercare can convert a controlled injury into infection, delayed healing, pigmentary change, or scarring.

Realistic expectations

Unrealistic expectations about the degree of improvement, discomfort, downtime, or complication risk should be addressed before treatment.

Failure to reach informed agreement about recovery and likely results is a reason to defer the procedure, even when there is no medical contraindication.

Pregnancy and breastfeeding

Pregnancy or breastfeeding requires a procedure-specific risk-benefit assessment and, when appropriate, consultation with the patient’s obstetric clinician.

These states are not uniformly classified as absolute contraindications for every resurfacing method, but elective deep resurfacing is commonly deferred when safety data, medications, or postoperative management are uncertain.

Understanding the Trade-offs

Not every risk factor is an absolute contraindication

Active infection, significant immunosuppression, current or recent oral isotretinoin use, and a strong keloid tendency may require avoiding or postponing deep resurfacing.

By contrast, darker skin phototype, prior HSV, controlled connective-tissue disease, smoking history, hormone exposure, and prior procedures may require treatment modification or additional precautions rather than automatic exclusion.

“Relative” does not mean insignificant

A relative contraindication can become unacceptable when several risks occur together. For example, a patient with darker skin, active melasma, recent UV exposure, and a history of post-inflammatory hyperpigmentation may face a poor risk-benefit balance even if each factor is considered manageable in isolation.

Device choice does not eliminate screening requirements

Er:YAG systems and conservative protocols may reduce some risks compared with aggressive CO2 treatment, but they do not remove the need to screen for infection, abnormal scarring, impaired healing, HSV, pigmentary disease, or anatomical eyelid risk.

The patient’s biology and treatment area remain central determinants of safety.

Making the Right Choice for Your Goal

Screening should produce a documented decision to proceed, modify the protocol, or defer treatment.

If your primary focus is preventing delayed healing: Confirm the absence of current or recent oral isotretinoin use, active connective-tissue disease, prior radiation-related tissue damage, smoking-related vascular compromise, and significant immune impairment.
If your primary focus is preventing infection: Exclude active bacterial, viral, or fungal disease, assess HSV history, and establish antiviral prophylaxis when indicated for ablative full-face or perioral treatment.
If your primary focus is preventing scarring: Screen for keloids, hypertrophic scars, prior burns, dermal fibrosis, deep prior procedures, and other evidence of abnormal wound repair.
If your primary focus is controlling pigmentation: Assess Fitzpatrick phototype, melasma, prior hyperpigmentation, estrogen-related risk, photosensitizing medications, and recent UV exposure.
If your primary focus is safe periorbital treatment: Review prior external lower blepharoplasty and examine eyelid laxity before treating the infraorbital region.
If your primary focus is informed consent and recovery: Confirm realistic expectations and the patient’s ability to comply with wound care, sun avoidance, antiviral treatment, and follow-up.

A safe deep resurfacing decision begins with patient biology and risk assessment, not with the choice of laser or energy setting.

Summary Table:

Contraindication	Risk	Action
Oral isotretinoin use	Impaired healing	Defer 6-12 months
Active infection	Spread/infection	Defer until resolved
HSV history	Viral reactivation	Prophylactic antivirals
Keloid tendency	Scarring	Avoid or conservative
Dark skin type	Hyperpigmentation	Modify settings
Recent UV exposure	Pigment issues	Defer until baseline
Smoking	Delayed healing	Defer or modify
Immunosuppression	Infection risk	Modify or defer
Prior lower blepharoplasty	Ectropion	Conservative or avoid
Poor aftercare ability	Complications	Defer if noncompliant

Ready to enhance your practice with safe, advanced resurfacing? At BELIS, we offer professional-grade aesthetic devices like CO2 Fractional and Erbium lasers, designed for clinics and premium salons. Our solutions help you achieve optimal results while prioritizing patient safety. Contact us today to schedule a consultation and discover how our technology can elevate your treatments. Get in touch with BELIS now!